In the Beginning, Lipoproteins Cross the Endothelial Barrier
- PMID: 38616110
- PMCID: PMC11150724
- DOI: 10.5551/jat.RV22017
In the Beginning, Lipoproteins Cross the Endothelial Barrier
Abstract
Atherosclerosis begins with the infiltration of cholesterol-containing lipoproteins into the arterial wall. White blood cell (WBC)-associated inflammation follows. Despite decades of research using genetic and pharmacologic methods to alter WBC function, in humans, the most effective method to prevent the initiation and progression of disease remains low-density lipoprotein (LDL) reduction. However, additional approaches to reducing cardiovascular disease would be useful as residual risk of events continues even with currently effective LDL-reducing treatments. Some of this residual risk may be due to vascular toxicity of triglyceride-rich lipoproteins (TRLs). Another option is that LDL transcytosis continues, albeit at reduced rates due to lower circulating levels of this lipoprotein. This review will address these two topics. The evidence that TRLs promote atherosclerosis and the processes that allow LDL and TRLs to be taken up by endothelial cells leading to their accumulation with the subendothelial space.
Conflict of interest statement
None.
Similar articles
-
Triglyceride-rich lipoproteins and cardiovascular diseases.Front Endocrinol (Lausanne). 2024 May 31;15:1409653. doi: 10.3389/fendo.2024.1409653. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38883601 Free PMC article. Review.
-
Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.Cardiovasc Res. 2015 Sep 1;107(4):579-89. doi: 10.1093/cvr/cvv192. Epub 2015 Jul 9. Cardiovasc Res. 2015. PMID: 26160324
-
Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.J Cardiol. 2014 Jan;63(1):60-8. doi: 10.1016/j.jjcc.2013.06.018. Epub 2013 Sep 7. J Cardiol. 2014. PMID: 24016623
-
Triglyceride-Rich Lipoproteins: Their Role in Atherosclerosis.Rev Invest Clin. 2022 Mar 15;74(2):061-070. doi: 10.24875/RIC.21000416. Rev Invest Clin. 2022. PMID: 34759386
-
The atherogenic lipoprotein phenotype and vascular endothelial dysfunction.Atherosclerosis. 1998 Jun;138(2):229-35. doi: 10.1016/s0021-9150(98)00037-9. Atherosclerosis. 1998. PMID: 9690905 Review.